<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02810509</url>
  </required_header>
  <id_info>
    <org_study_id>Warfarin TTR-01</org_study_id>
    <nct_id>NCT02810509</nct_id>
  </id_info>
  <brief_title>Quality of Anticoagulation With Warfarin in Patient With Atrial Fibrillation for Secondary Stroke Prevention in Korea</brief_title>
  <official_title>Quality of Anticoagulation With Warfarin in Patient With Atrial Fibrillation for Secondary Stroke Prevention in Korea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inje University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Inje University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current study aims to assess the quality of anticoagulation with warfarin in real world
      practice of secondary stroke prevention in Korean patients with Atrial fibrillation (AF) and
      to explore predictors for poor International Normalized Range (INR) control.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  To assess the quality of anticoagulation with warfarin in real world practice of Korea
           for secondary stroke prevention in patients with AF-related Cardioembolic (CE) stroke 1)
           who initiated warfarin therapy and treatment at least for more than 7 days of warfarin
           adjustment period (warfarin-initiated cohort), and 2) who initiated and maintained
           warfarin therapy at least for more than 90 days after the 7 days of warfarin adjustment
           period (long-term warfarin-treated cohort).

        -  To explore predictors for poor INR control.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Time in TTR, the proportion of time in the therapeutic range of INR between 2.0-3.0.</measure>
    <time_frame>We will analyze INR data of patients who had AF-related ischemic stroke and were treated with warfarin therapy at least for more than 7 days of warfarin adjustment period. (The INR follow up duration: 1 ~ maximum 3 years)</time_frame>
    <description>The primary outcome is TTR as measured by the proportion of time in the therapeutic range of INR between 2.0-3.0, using the Rosendaal linear interpolation method.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of INR in the therapeutic range of 2.0-3.0: numbers of INR within the therapeutic range by the total numbers of INR measured.</measure>
    <time_frame>We will analyze INR data of patients who had AF-related ischemic stroke and were treated with warfarin therapy at least for more than 7 days of warfarin adjustment period. (The INR follow up duration: 1 ~ maximum 3 years)</time_frame>
    <description>The secondary outcome is the proportion of INR in the therapeutic range of 2.0-3.0: numbers of INR measures within the therapeutic range divided by the total numbers of INR measured.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">2217</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>Warfarin-initiated cohort</arm_group_label>
    <description>Admission due to AF-related ischemic stroke
Initiation of warfarin therapy and treatment at least for more than 7 days of warfarin adjustment period
For Time in therapeutic range (TTR) calculation, available consecutive INR values ≥3 after the 7 days of warfarin adjustment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Long term Warfarin-treated cohort</arm_group_label>
    <description>Admission due to AF-related ischemic stroke
Long-term warfarin therapy at least for more than 90 days after the 7 days of warfarin adjustment period
For Time in TTR calculation, available consecutive INR values ≥3 after the 7 days of warfarin adjustment
TTR evaluable days ≥ 90 days</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Consecutive patients who admitted to 16 participating centers due to AF-related ischemic
        stroke between Jan 1, 2011 and Dec 31, 2012 and started warfarin therapy for secondary
        stroke prevention will be enrolled in this study. The number of patients is expected to be
        2,217 for the warfarin-initiated cohort and 1,057 for the long-term warfarin-treated
        cohort.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Inclusion criteria for the warfarin-initiated cohort

          1. Admission due to AF-related ischemic stroke

          2. Initiation of warfarin therapy and treatment at least for more than 7 days of warfarin
             adjustment period

          3. For TTR calculation, available consecutive INR values ≥3 after the 7 days of warfarin
             adjustment

        Inclusion criteria for the long-term warfarin-treated cohort

          1. Admission due to AF-related ischemic stroke

          2. Long-term warfarin therapy at least for more than 90 days after the 7 days of warfarin
             adjustment period

          3. For TTR calculation, available consecutive INR values ≥3 after the 7 days of warfarin
             adjustment

          4. TTR evaluable days ≥ 90 days

        Exclusion Criteria:

          1. AF with mechanical valve

          2. Enrollment in anticoagulation randomized clinical trial

          3. Enrollment in studies affecting the target INR range.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Keun-Sik Hong, MD, Phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Neurology, Ilsan Paik Hospital Inje University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Keun-Sik Hong, MD, Phd</last_name>
    <phone>031-910-7277</phone>
    <email>nrhks@paik.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hallym University College of Medicine</name>
      <address>
        <city>Anyang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Byung-Chul Lee, MD, Phd</last_name>
      <email>ssbrain@hallym.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dong-A University College of Medicine</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jae Kwan Cha, MD, Phd</last_name>
      <email>nrcjk65@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yeungnam University School of Medicine</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Lee, MD, Phd</last_name>
      <email>junleeluke@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dongguk University Ilsan Hospital</name>
      <address>
        <city>Goyang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dong-Eog Kim, MD, Phd</last_name>
      <email>kdongeog@duih.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Medical School</name>
      <address>
        <city>Gwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Man-Seok Park, MD, Phd</last_name>
      <email>mspark@jnu.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ilsan Paik Hospital Inje University</name>
      <address>
        <city>Ilsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keun-Sik Hong, MD, Phd</last_name>
      <email>nrhks@paik.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inha University Hospital</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jung-Ho Rha, MD, Phd</last_name>
      <email>jhrha@inha.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jeju National University Hospital, Jeju National University College of Medicine</name>
      <address>
        <city>Jeju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jay Chol Choi, MD, Phd</last_name>
      <email>iguazzu@hanmail.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hee-Joon Bae, MD, Phd</last_name>
      <email>braindoc@snu.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Eulji General Hospital, Eulji University School of Medicine</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jong-Moo Park, MD, Phd</last_name>
      <email>pjm0407@chol.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Korea University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun-Young Lee, MD, Phd</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center, Sungkyunkwan University School of Medicine</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oh Young Bang, MD, Phd</last_name>
      <email>nmboy@unitel.co.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tai Hwan Park, MD, Phd</last_name>
      <email>strokezero@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Byung-Woo Yoon, MD, Phd</last_name>
      <email>bwyoon@snu.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Soonchunhyang University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyung Bok Lee, MD, Phd</last_name>
      <email>bogouss@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Soonchunhyang University</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yang-ki Kim, MD, Phd</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Ulsan College of Medicine</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sun Uck Kwon, MD, Phd</last_name>
      <email>sunkwon7@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yonsei University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyo Suk Nam, MD, Phd</last_name>
      <email>hsnam@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 23, 2015</study_first_submitted>
  <study_first_submitted_qc>June 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2016</study_first_posted>
  <last_update_submitted>June 20, 2016</last_update_submitted>
  <last_update_submitted_qc>June 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Inje University</investigator_affiliation>
    <investigator_full_name>Keun-Sik Hong</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Wafarin</keyword>
  <keyword>Cardioembolic (CE) stroke</keyword>
  <keyword>ischemic stroke</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>January 25, 2017</submitted>
    <returned>March 14, 2017</returned>
    <submitted>March 14, 2017</submitted>
    <returned>April 24, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

